Think Bioscience, a small molecule discovery company, and CrystalsFirst, a leader in structure-based drug discovery solutions, have expanded their partnership.

Their ongoing collaboration has led to the identification of novel mechanisms of action for several difficult targets in Think Bioscience’s pipeline. 

This expanded partnership underscores the commitment of Think Bioscience and CrystalsFirst to push the boundaries of drug discovery for challenging targets.

In their initial collaboration, Think Bioscience’s researchers worked closely with CrystalsFirst’s team to apply the MAGNET platform to challenging targets. This approach rapidly generated abundant structural data, enabled by the SmartSoak-technology. 

Jerome Fox, Ph.D., co-founder and Chief Executive Officer of Think Bioscience, said, “CrystalsFirst’s MAGNET platform exceeded our expectations by rapidly delivering high-resolution structural data, including novel mechanistic insights, to guide medicinal chemistry. We look forward to expanding our partnership with CrystalsFirst to leverage their platform across even more targets.”

The structural data and structure-guided compound designs have accelerated the progression from targets to lead candidates and unveiled new binding mechanisms. These insights are enabling Think Bioscience to devise therapeutic strategies that were not possible using conventional methods.

Building on their early success, the two companies will expand their collaboration to include additional pipeline programs and expanded use of the MAGNET platform. 

By continuing to integrate CrystalsFirst’s structural biology capabilities early in the discovery process, Think Bioscience aims to accelerate first-in-class drug programs that address high unmet medical needs. 

Serghei Glinca, Ph.D., co-founder and Chief Executive Officer of CrystalsFirst, commented, “By combining Think’s breakthrough biology with our MAGNET platform, we rapidly revealed tractable binding sites and novel chemistry for challenging targets. We are excited to expand our collaboration and continue fueling Think’s innovative pipeline with cutting-edge technology in structural biology and AI, ultimately accelerating the path from targets to promising drug candidates.”